Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus

References

• Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:29–39.
   Web of Science ®Google Scholar
• Pisetsky DS. Anti-DNA antibodies–quintessential biomarkers of SLE. Nat Rev Rheumatol. 2016;(2):102–10.
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Font J, Sebatiani GD, Gil A, Lavilla P, European Working Party on Systemic Lupus Erythematosus, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine. 2003;82:299–308.
   PubMed Web of Science ®Google Scholar
• Doria A, Canova M, Tonon M, Zen M, Rampudda E, Bassi N, et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev. 2008;8:24–8.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Clarke A, Gladman DD, Urowitz M, Fortin PR, Barr SG, et al. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus. 2006;15(12):835–9.
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum. 1999;42(9):1785–96.
   PubMedGoogle Scholar
• Doria A, Briani C. Lupus: improving long-term prognosis. Lupus. 2008;17(3):166–70.
   PubMed Web of Science ®Google Scholar
• Petri M. Long-term outcomes in lupus. Am J Manag Care. 2001;7:S480–S5.
   PubMed Web of Science ®Google Scholar
• Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43(8):1801–8.
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60(2):221–5.
   PubMed Web of Science ®Google Scholar
• Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929–39.
   PubMed Web of Science ®Google Scholar
• Clatworthy MR, Smith KG. B cells in glomerulonephritis: focus on lupus nephritis. Semin Immunopathol. 2007;29:337–53.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, BLISS-52 Study Group, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trail. Lancet 2011;377(9767):721–31.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98.
   PubMed Web of Science ®Google Scholar
• Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907–16.
   PubMed Web of Science ®Google Scholar
• Skaug B, Jiang X, Chen ZJ. The role of ubiquitin in NF-kappaB regulatory pathways. Annu Rev Biochem. 2009; 78:769–96.
   PubMed Web of Science ®Google Scholar
• Mattingly LH, Gault RA, Murphy WJ. Use of systemic proteasome inhibition as an immune-modulating agent in disease. EMIDDT. 2007;7:29–34.
   Google Scholar
• Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14:748–55.
   PubMed Web of Science ®Google Scholar
• Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86:1754–61.
   PubMed Web of Science ®Google Scholar
• Walsh RC, Alloway RR, Girnita AL, Woodle ES. Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int. 2012;81:1067–74.
   PubMed Web of Science ®Google Scholar
• van der Vlag J, Berden JH. Proteasome inhibition: a new therapeutic option in lupus nephritis? Nephrol Dial Transplant. 2008;23:3771–2.
   PubMed Web of Science ®Google Scholar
• Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia. 2007;21:30–6.
   PubMed Web of Science ®Google Scholar
• Fröhlich K, Holle JU, Aries PM, Gross WL, Moosig F. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis. 2011;70(7):1344–5.
   PubMed Web of Science ®Google Scholar
• de Groot KA, Tsang A, Sjoe M, Niewerth D, Cloos J, Blank JL, et al. Pharmacodynamic monitoring of (immuno) proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis. Lupus Sci Med 2015;2(1):e000121.
   PubMed Web of Science ®Google Scholar
• Alexander T, Sarfert R, Klotsche J, Kühl A, Rubbert-Roth A, Lorenz HM, et al. The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015;74:1474–8.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725
   PubMed Web of Science ®Google Scholar
• Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D, et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med. 2004;199(11):1577–84.
   PubMed Web of Science ®Google Scholar
• Mumtaz IM, Hoyer BF, Panne D, Moser K, Winter O, Cheng QY, et al. Bone marrow of NZB/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunity. J Autoimmun. 2012;39(3):180–8.
   PubMed Web of Science ®Google Scholar
• Khodadadi L, Cheng Q, Alexander T, Sercan-Alp Ö, Klotsche J, Radbruch A, et al. Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB/WF1 mice. PLoS One. 2015;10(8):e0135081.
   PubMed Web of Science ®Google Scholar
• Hirabayashi Y, Oka Y, Ikeda T, Fujii Ishii T, Sasaki T, Harigae H. The endoplasmic reticulum stress-inducible protein, Herp, is a potential triggering antigen for anti-DNA response. J Immunol. 2010;184:3276–83.
   PubMed Web of Science ®Google Scholar
• Lee WS, Sung MS, Lee EG, Yoo HG, Cheon YH, Chae HJ, et al. A pathogenic role for ER stress-induced autophagy and ER chaperone GRP78/BiP in T lymphocyte systemic lupus erythematosus. J Leukocyte Biol. 2015;97:425–33.
   PubMed Web of Science ®Google Scholar
• Yoshizawa K, Mukai H, Miyazawa M, Miyako M, Ogawa Y, Ohyashiki K, et al. Bortezomib therapy- related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization. Cancer Sci. 2014;105(2):195–201.
   PubMed Web of Science ®Google Scholar
• Ikeda T, Fujii H, Nose M, Kamogawa Y, Shirai T, Shirota Y, et al. Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity. Arthritis Res Ther. 2017;19(1):187.
   PubMed Web of Science ®Google Scholar